A US medical panel has recommended resuming use of the Johnson & Johnson COVID-19 vaccine.
The advice came from advisers to the US Centers for Disease Control and Prevention (CDC).
The vaccine was paused by the CDC and US Food and Drug Administration last week after eight “serious” cases of rare but serious blood clots associated with low blood platelets. One person died.
Johnson & Johnson’s vaccine, which is given as a single jab as opposed to the traditional two doses, has been given to almost eight million people in the US.
The American government is now likely to quickly resume use of the jab.
The EU medicines regulator said this week that the unusual blood clots should be listed as “very rare” side effects of the vaccine, but stressed the overall benefits outweighed the risks.
Johnson & Johnson decided to delay its rollout in Europe out of an “abundance of caution” while US authorities investigated the clots.
More from Covid-19
COVID-19: People dying on pavement as coronavirus crisis stretches India’s healthcare system to limit
COVID-19: UK reports another 40 coronavirus deaths and 2,678 cases
COVID-19: The crisis in one of India’s worst-hit cities, where someone dies every five minutes
COVID-19: Severe complications during pregnancy more likely if infected with coronavirus, study finds
COVID:19: Mask-free summer on the cards, as vaccines take control of the pandemic, say experts
COVID-19: UK government scientists investigating whether rats could infect humans, official documents reveal
All eight US cases were in people under 60 and they developed clots within three weeks of vaccination, the EMA said, with the majority of them women.
They were “very similar to the cases that occurred with the coronavirus vaccine developed by AstraZeneca”, the regulator added.
The vaccine has not yet been approved for use in the UK, but 30 million doses have been ordered.
A member of the US panel that recommended resuming use of the Johnson & Johnson jab said the benefits “clearly outweigh the risk from a population and individual perspective”.
“It’s a new risk. It’s admittedly an extremely small risk and smaller than many other risks that we choose to take every day,” said Dr Beth Bell from the University of Washington.
Earlier this month, the EMA resumed the rollout of the AstraZeneca vaccine following reports of rare blood clots.